Matthias Gromeier, MD

Professor of Neurosurgery
Professor in Molecular Genetics and Microbiology
Professor in Medicine
Member of the Duke Cancer Institute
Campus mail Box 3020 Med Ctr, Durham, NC 27710
Phone (919) 668-6205
Email address grome001@mc.duke.edu

I am a classically trained virologist with a focus on molecular mechanisms of RNA virus pathogenesis. My career is dedicated to unraveling RNA virus:host relations and devising methods of exploiting them for cancer immunotherapy and vaccine design. My background is in translation regulation and mRNA metabolism, viral RNA sensing and innate immunity, and cancer immunology and immunotherapy. Basic mechanistic research in my laboratory is supporting an ambitious clinical translational research program with active multi-center clinical trials in several cancer indications. 

Education and Training

  • Postdoctoral Associate, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1996 - 1999
  • Postdoctoral fellow, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1993 - 1996
  • M.D., University of Hamburg (Germany), 1992

Publications

Walton, Ross, Michael Brown, Eda Holl, David Boczkowski, Vidya Chandramohan, Smita Nair, and Matthias Gromeier. “PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus.” In Journal for Immunotherapy of Cancer, Vol. 5. BMC, 2017.

Scholars@Duke

Brown, Michael C., Eda K. Holl, David Boczkowski, Elena Dobrikova, Mubeen Mosaheb, Vidya Chandramohan, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.” Sci Transl Med 9, no. 408 (September 20, 2017). https://doi.org/10.1126/scitranslmed.aan4220.

PMID
28931654
Full Text

Desjardins, Annick, John H. Sampson, Gordana Vlahovic, Katherine B. Peters, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).” In Journal of Clinical Oncology, 35:e13533–e13533. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13533.

Full Text

Holl, Eda K., Michael C. Brown, David Boczkowski, Megan A. McNamara, Daniel J. George, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.” Oncotarget 7, no. 48 (November 29, 2016): 79828–41. https://doi.org/10.18632/oncotarget.12975.

PMID
27806313
Full Text

Holl, E., M. Brown, D. Boczkowski, D. Bigner, M. Gromeier, and S. Nair. “POLIO VIRUS THERAPY HAS IMMUNOSTIMULATORY PROPERTIES THAT ARE ACTIVE AGAINST SOLID TUMORS.” In Cytokine, 87:61–62. ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2016.

Scholars@Duke

Mosaheb, M Mubeen, Elena Dobrikova, Michael C. Brown, Christopher Pirozzi, Vidyalakshmi Chandramohan, Eda Holl, Smita Nair, and Matthias Gromeier. “Abstract A032: Using oncolytic polio expressing tumor as a cancer vaccine.” In Antigens and Vaccines. American Association for Cancer Research, 2016. https://doi.org/10.1158/2326-6066.imm2016-a032.

Full Text

Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.

Full Text

Pages